The Future of Clinical Trials: A Shift from Artificial to Augmented to Applied Intelligence

By Danélia Botes

December 20, 2023

The Present Situation Regarding Clinical Trials

Clinical trials, the bedrock of medical advancements, must embrace significant innovation. With global spending on these trials exceeding $50 billion now and predicted to reach over $85 billion by 2030, we must question the value we’re getting from this rapidly growing industry. What is the role of Artificial intelligence (AI) in clinical trials?  There are frequently chances to address chronic health disorders that are hampered by the time and costs associated with major trials. Despite the fact that there is a clear demand for improved evidence that is supplied in a more expedient manner through clinical trials that are efficient, the fundamental costs of the majority of clinical trials have not changed.

The Role of Artificial Intelligence in Clinical Trials

AI is reshaping both scientific research and medical practice. AI holds immense potential to transform clinical research, from improving human judgement to automating tasks. Manual transfer and verification of data account for a significant portion of clinical trial costs. These processes are ripe for automation. Therefore, the breakthrough in clinical trials likely requires the integration of AI. 

Natural Language Processing in Clinical Trials

In a recent study, authors investigated if Natural Language Processing (NLP) models could effectively classify heart failure hospitalisations. They found a high agreement level between the NLP model and the trial-adjudicated case outcomes. This finding suggests that using AI for event adjudication could save significant time and costs. However, they have not yet identified the requirements for calibration, validation, and periodic performance assessment during the scaling process.

The Prospects for Artificial Intelligence in Clinical Trials

AI can significantly improve the development, execution, and dissemination of clinical trials. It can enhance efficiency and remove bias in areas like participant identification, study procedure generation, and trial material production. However, we need an oversight structure to ensure the trials don’t incorporate previous biases. By addressing the risks properly, we can safely and ethically realise the benefits of artificial intelligence in clinical trials. 

In conclusion, recent studies show that AI-enhanced clinical research is achievable and potentially beneficial. As we learn more, we must find ways to honestly communicate our limitations and failures without damaging the process’s integrity. High-quality evaluations of AI tools, using rigorous designs and analysis, are crucial to provide quality information about the benefits and risks of using AI in clinical trials. We need these kinds of publications to support the research behind AI-enhanced clinical trials and maintain trust in AI applications for these trials. 

Reference url

Recent Posts

Opdivo lung cancer approval
           

FDA’s Opdivo Lung Cancer Approval

🚀 The FDA has made a groundbreaking move by approving Opdivo (nivolumab) as a neoadjuvant treatment for resectable non-small cell lung cancer (NSCLC). This new regimen, combining Opdivo with platinum-doublet chemotherapy, aims to enhance patient outcomes pre- and post-surgery. With promising results from recent clinical trials, it’s a significant step forward in cancer care!

Learn more about this advancement and its implications for patients.

#SyenzaNews #CancerCare #FDAApproval

Mental Healthcare for Youth
                   

Mental Healthcare for Youth: Addressing Substance Use and Chronic Conditions

🌍🧠 Today, on World Mental Health Day, let’s focus on the mental well-being of our youth. With one in seven adolescents experiencing mental disorders, it’s crucial to address the challenges they face in accessing care. Innovative solutions like telemedicine and school-based programmes offer hope.
Let’s advocate for policies that prioritise youth mental health. Together, we can create a supportive environment for young people to thrive. 🌟
#SyenzaNews #WorldMentalHealthDay #YouthMentalHealth #MentalHealthAwareness

elacestrant breast cancer therapy
         

NICE Collaborates with Menarini to Evaluate Elacestrant Breast Cancer Treatment

🔍 The conversation surrounding elacestrant for advanced breast cancer is gaining momentum! The National Institute for Health and Care Excellence (NICE) is working closely with Menarini Stemline to address critical uncertainties in evidence. As this drug aims to tackle oestrogen receptor-positive, HER2-negative breast cancers with activating ESR1 mutations, public consultation is underway until 22 October 2024.

Stay informed about potential advancements in treatment options and the importance of collaboration in healthcare.

#SyenzaNews #BreastCancer #HealthcareInnovation

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.

SPEAK WITH US

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

JOIN NEWSLETTER




SERVICES

© 2024 Syenza™. All rights reserved.